Secondary Malignant Neoplasm — Trials

Secondary Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

14,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,275
Recruiting: 2,321
Ph III recruiting: 272
Growth YoY: +12.3%
Industry share: 22%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,961)

clinicaltrialsPublishedShowing 501–550 of 636 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05189730	Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC(ETNT)	active not recruiting	Phase 2	80	Sichuan Cancer Hospital and Research InstituteOTHER	1	Nov 20, 2025	clinicaltrials
NCT04425018	MARGetuximab Or Trastuzumab (MARGOT)(MARGOT)	active not recruiting	Phase 2	174	Dana-Farber Cancer InstituteOTHER	1